Karelizumab generally refers to Karelizumab for Injection, which usually develops resistance between months and years. Injectable carelizumab is an antitumor drug that is commonly used in the treatment of Hodgkin’s lymphoma, hepatocellular carcinoma, nasopharyngeal carcinoma, and other diseases. The time of resistance to Carrelizumab for Injection is between several months and several years, but there is no clear data to show that it is mainly related to the degree of tolerance of patients, the degree of disease, physical fitness and so on. If the patient is allergic to the active ingredient or excipients in Karelizumab for Injection, the drug is contraindicated. Carelizumab for Injection is used with caution in elderly people over 65 years of age, and those who have experienced serious adverse reactions and life-threatening reactions during previous treatment with other immune-stimulating anticancer drugs. Patients are advised to follow the doctor’s instructions to apply Carilizumab for Injection, and communicate with the doctor in time when accompanied by uncomfortable symptoms during the use of the drug, so as to take effective treatment measures to prevent the occurrence of unexpected situations.